Comparison of Efficacy & Tolerability Of PEG 4000 Versus PEG 3350+ Electrolytes for Pediatric Fecal Disimpaction
NCT06349031 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2024-04-12
Summary
Childhood constipation is a common but serious gastrointestinal disorder prevalent worldwide. In 90-95% of children, it is of functional origin. Thirty to seventy-five percent of children with functional constipation also have fecal impaction. The treatment strategy for functional constipation includes fecal disimpaction and maintenance therapy to ensure regular bowel movements.
Polyethylene glycol (PEG) based laxatives have been recommended as the first-line therapeutic agents. The commonly used formulations are PEG 3350 with a molecular weight between 3200- 3700 g/mol and PEG 4000 with molecular weight of 4000 g/mol. Both are shown to be effective in pediatric constipation management in placebo-controlled trials. PEG 3350 + Electrolyte (E) is more widely used than PEG 4000 for the management of constipation. This might be because of the perception that PEG 3350 + E is safer in terms of preventing electrolyte imbalance. However, because of the inclusion of electrolytes, PEG 3350+ E solution taste saltier than PEG 4000. Many patients struggle to tolerate the unpleasant taste resulting in the high incidence of non-compliance. To date, no pediatric trials have compared PEG 4000 versus PEG 3350+E for management of Fecal disimpaction.
Present study has been planned to evaluate the efficacy \& tolerability of PEG 4000 versus PEG 3350+ E for fecal disimpaction in pediatric functional constipation. Patients between age 1-16 years having functional constipation (as per ROME IV criteria) with fecal impaction will be included. Subjects will be randomly assigned to either PEG 4000 or PEG 3350+E at a ratio of 1:1. They will be stratified into 3 different age groups: 1-5 years, 6-11 years, and 12-16 years. They will receive either of the PEG solutions (as per allocation) at a dose of 1.5 gm/kg/day for 6 consecutive days or till the resolution of fecal impaction whichever is earlier. The resolution of fecal impaction is defined as the passage of clear liquid stool and the disappearance of palpable abdominal fecolith.
Primary outcome is defined as the proportion of subjects achieving fecal disimpaction in each arm.
Secondary outcomes are defined as follows:
1. Total no of Days required to achieve fecal disimpaction in each arm
2. Cumulative dose of PEG required for fecal disimpaction in each arm
3. Proportion of subjects (\> 5 years age) reporting palatability issues in each arm
4. Proportion of subjects discontinuing the treatment due to palatability issues in each arm
Conditions
- Functional Constipation
- Fecal Impaction
- Constipation - Functional
- Constipation Chronic Idiopathic
- Pediatric Functional Constipation
Interventions
- DRUG
-
Administration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants
As per treatment allocation, PEG 4000 will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
- DRUG
-
Administration of Polyethylene Glycol (PEG) 3350 + Electrolyte as per treatment allocation to participants
As per treatment allocation, PEG 3350 + Electrolytes will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
Sponsors & Collaborators
-
Institute of Medical Sciences and SUM Hospital
lead OTHER
Principal Investigators
-
Kalpana Panda, MD, DM · Associate Professor
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Year
- Max Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-04-15
- Primary Completion
- 2024-09-15
- Completion
- 2024-09-15
Countries
- India
Study Locations
More Related Trials
-
PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children
NCT00153114 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison Trial of Enema vs. PEG 3350 for Constipation
NCT00467350 ·Status: TERMINATED ·Phase: NA
-
To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.
NCT00255372 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)
NCT02292459 ·Status: WITHDRAWN ·Phase: PHASE3
-
Prucalopride in Pediatric Subjects With Functional Constipation
NCT01330381 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)
NCT01212445 ·Status: COMPLETED ·Phase: PHASE2
-
RCE With FMT in the Treatment of Childhood Constipation
NCT05035784 ·Status: COMPLETED ·Phase: NA
-
Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications
NCT00153127 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy Side Effects and the Tolerance of Polyethylene Glycol 3350 as a Bowel Prep in Children
NCT01164410 ·Status: COMPLETED
-
Effectiveness & Safety of Promelaxin® Microenemas Against Macrogol 4000 P.O. in Chronic Constipation in Children 6-48 Months
NCT02751411 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial to Evaluate the Efficacy and Safety of PMF104 Compared to a Conventional PEG-electrolyte Solution in Children
NCT03106922 ·Status: UNKNOWN ·Phase: PHASE3
-
A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children
NCT00319670 ·Status: COMPLETED ·Phase: PHASE4
-
Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children
NCT01518790 ·Status: COMPLETED ·Phase: NA
-
A Study of Prucalopride For Functional Constipation in Children and Teenagers
NCT04759833 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years.
NCT03177434 ·Status: UNKNOWN ·Phase: PHASE4
-
Different Bowel Preparations for Colonoscopy In Children
NCT01711437 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation of One-day Polyethylene Glycol Powder Solution for Colonoscopy in Children
NCT01626040 ·Status: COMPLETED
-
Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation
NCT00153140 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)
NCT01885104 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation
NCT00603681 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome
NCT00765557 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Movicol in Childhood Constipation (ProMotion Study)
NCT00404040 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of PEG 3350 for Treatment of Chronic Constipation
NCT03957668 ·Status: UNKNOWN ·Phase: PHASE3
-
PEG Versus PEG+Bisacodyl Versus Sennosides for Colon Cleansing Before Colonoscopy
NCT01531140 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Triple Management Program in the Management of Functional Chronic Constipation in Children
NCT06082622 ·Status: COMPLETED ·Phase: NA